Cost-related nonadherence with glaucoma medications in Ontario.


Journal

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
ISSN: 1715-3360
Titre abrégé: Can J Ophthalmol
Pays: England
ID NLM: 0045312

Informations de publication

Date de publication:
12 2021
Historique:
received: 10 08 2020
revised: 16 11 2020
accepted: 09 01 2021
pubmed: 7 2 2021
medline: 15 12 2021
entrez: 6 2 2021
Statut: ppublish

Résumé

To determine the proportion of glaucoma patients in Ontario aged 25-64 who lack insurance coverage for glaucoma medications and to assess the frequency of cost-related nonadherence to glaucoma medications. Cross-sectional study. Glaucoma patients on medication from 2 glaucoma clinics in Toronto, Ontario. 100 consecutive glaucoma patients aged 25-64 (not entitled to provincial drug benefit) and 100 consecutive glaucoma patients aged 65+ (entitled to provincial drug benefit), all on topical glaucoma therapy, completed a standardized questionnaire. Questions included insurance coverage for glaucoma medications, cost concerns when paying for glaucoma medications, cost-related nonadherence, and sociodemographics. 25.8% of those aged 25-64 express concerns about the cost of their glaucoma medications compared to 7.1% of those aged 65+ (p < 0.001). Patients aged 25-64 were also significantly more likely to report at least one form of cost-related nonadherence (15.5% vs 2.0%, p = 0.001) and significantly more likely to report missing eye drops in a given week than patients aged 65+ (32.0% vs 16.7%, p = 0.01). 17% (95% confidence interval 11%-26%) of patients aged 25-64 self-reported having no insurance coverage for their glaucoma medications. Of those with coverage, the most common source of insurance was employer-sponsored (68.6%) with 44% requiring a copayment. The average copayment was $18 (range $2-$250) for those aged 25-64 compared with $5 in the 65+ group (range $0.62-$100). 17% of glaucoma patients aged 25-64 do not have coverage for their drops. One in four expressed concerns about the cost of their glaucoma medications, and 15.5% reported cost-related nonadherence.

Identifiants

pubmed: 33548175
pii: S0008-4182(21)00018-1
doi: 10.1016/j.jcjo.2021.01.008
pii:
doi:

Substances chimiques

Antihypertensive Agents 0
Ophthalmic Solutions 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

379-384

Informations de copyright

Copyright © 2021 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.

Auteurs

Yvonne M Buys (YM)

Department of Ophthalmology and Vision Sciences. Electronic address: y.buys@utoronto.ca.

Dov Kagan (D)

Department of Ophthalmology and Vision Sciences.

Ya-Ping Jin (YP)

Department of Ophthalmology and Vision Sciences; Dalla Lana School of Public Health University of Toronto, Toronto, Ont.

Graham E Trope (GE)

Department of Ophthalmology and Vision Sciences.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH